EUVIMEDEUVIMED entdecken
Crossref

Methodological considerations in the interpretation of ASCENT-03

Francesca Poggio, Daniele Generali

European Journal of Cancer · 2026-09 · 245 · 116962

DOI: 10.1016/j.ejca.2026.116962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-09. Verfasst von Francesca Poggio und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinica di Oncologia Medica, AOM - IRCCS Ospedale Policlinico San Martino, Genova, Italy. Electronic address: francescabenedetta.poggio@aomliguria.it. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Camptothecin, Antibodies, Monoclonal, Humanized, Randomized Controlled Trials as Topic. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Results of the ASCENT-03 trial demonstrated a statistically significant improvement in progression-free survival with sacituzumab govitecan (SG) compared with chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (mTNBC) ineligible for PD-(L)1 inhibitors. This population represents a clear unmet need, as PD-L1 CPS < 10 tumours account for a substantial proportion of mTNBC and many patients do not receive subsequent lines of therapy. However, several methodological considerations temper the strength of the conclusions, underlining the need for mature, crossover-adjusted overall survival analyses before definitively establishing SG as a first-line standard of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCamptothecinAntibodies, Monoclonal, HumanizedRandomized Controlled Trials as TopicHumansFemaleProgression-Free SurvivalAntineoplastic Agents

Stichwörter der Autor:innen

breast cancerchemotherapysacituzumab govitecantriple negative

Substanzen

CamptothecinAntibodies, Monoclonal, HumanizedAntineoplastic Agents

Autor:innen und Institutionen

  • Clinica di Oncologia Medica, AOM - IRCCS Ospedale Policlinico San Martino, Genova, Italy. Electronic address: francescabenedetta.poggio@aomliguria.it.
  • Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

Zitieren

APA

Poggio, F., & Generali, D. (2026). Methodological considerations in the interpretation of ASCENT-03. European Journal of Cancer, 245, 116962. https://doi.org/10.1016/j.ejca.2026.116962

Vancouver

Poggio F, Generali D. Methodological considerations in the interpretation of ASCENT-03. European Journal of Cancer. 2026;245:116962. doi:10.1016/j.ejca.2026.116962

BibTeX
@article{Poggio2026,
  author = {Poggio, Francesca and Generali, Daniele},
  title = {Methodological considerations in the interpretation of ASCENT-03},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {245},
  pages = {116962},
  doi = {10.1016/j.ejca.2026.116962}
}
Kostenlos starten →